Gerrit-Jan Liefers, MD of Leiden University Medical Center discusses the SABCS 2020 Abstract – The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in patients aged ≥70 years from the population-based observational FOCUS cohort.
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS-NOVEMBER 17, 2020-Agendia, Inc., a global pioneer in precision oncology for breast cancer, today announced that it would present new evidence from ongoing clinical trials examining the genomic studies of MammaPrint® and BluePrint® at the San Antonio Breast Cancer Symposium (SABCS 2020) on December 8-11, 2020.
These statistics, based on current clinical studies demonstrating the effectiveness of MammaPrint and BluePrint testing to reliably inform optimal care planning, illustrate the many ongoing trials of Agendia that will eventually affect patient treatment and performance.
Relevant data chosen for discussions of poster spotlights include:
Performance of BluePrint in predicting the gain of pertuzumab in genomically HER2-positive patients: biomarker review of the APHINITY trial
The following authors: Krop, I., et al.
Session: Discussion 3 of the Spotlight Poster | Wednesday, December 9, 2020 | 6:30pm-7:30pm CST
PD3-01 Poster #:
5-year NBRST research results: Preoperative breast cancer subtypes of MammaPrint and BluePrint are correlated with neoadjuvant care response and survival.
The following authors: Whitworth, P., et al.
Session: Discussion of the Spotlight Poster 9 | Thursday, December 10, 2020 | 3:30pm-4:45pm CST
PD9-01 Poster #:
“Laura van’t Veer, Ph.D., co-founder and Chief Research Officer at Agendia, will also give an oral presentation on an abstract entitled “How low is low risk: MINDACT updated outcome and treatment gain in patients deemed to be a low clinical risk and stratified by genomic signature, age, and nodal status.
Details of additional Agendia abstracts that have been approved for SABCS 2020 include the following:
How Low Is Low Risk: In patients deemed to be clinically low risk and stratified by genomic signature, age and nodal status, MINDACT modified outcome and treatment benefits
Authors: L.J., et al., van’t Veer.
Conference: General Session 4 | Friday 11 December 2020 | 8:45 am to 11:30 am CST | 8:45 am to 11:30 am CST
PS6-01 Poster #:
Speech #: Oral Speech GS4-11 | Speech 11:15am-11:25am CST | Live Q&A Session 11:25am-11:30am CST
BluePrint molecular subtyping enhances the estimation of therapeutic responses and survival outcomes in patients with discordant clinical and genomic classifications.
The following authors: Whitworth, P., et al.
Session: Poster Session 4 Poster Session
Poster #: PS4-04 Poster #:
The 70-gene signature (MammaPrint) reliably predicts the risk of recurrence of distant breast cancer from the population-based retrospective FOCUS cohort of patients aged ~70 years.
Authors: I., et al., Noordhoek.
Meeting: Poster Session 6
PS6-06 Poster #:
Comparison of findings from MammaPrint and BluePrint between core needle biopsy and breast cancer surgical resection specimens
The following authors: McKelley, J., et al.
Meeting: Poster Session 6
PS6-19 Poster #: PS6-19
As prognostic factors for elderly patients with early-stage breast cancer, MammaPrint, and BluePrint
Authors: P.W., et al., Blumencranz.
Meeting: Poster Session 6
PS6-41 Poster #:
Basal-type breast cancer ethnic disparities: clinical and molecular characteristics of obese African American and Caucasian patients.
Authors: Sharma, D., et al., respectively
Session: Poster Session 7 Poster Session
PS7-68 Poster #:
Molecular profiles and clinical-pathological characteristics of patients with Asian early-stage breast cancer
Authors: Chen, M., and others, et al.
Session: Poster Session 7 Poster Session
PS7-69 Poster #:
MammaPrint and BluePrint differential gene expression study and clinical utility in male breast cancer patients
The following authors: Crozier, J., et al.
Meeting: Poster Session 14
Poster #: PS14-11 Poster #:
Differential gene expression by MammaPrint in invasive lobular carcinoma of Luminal form and invasive ductal carcinoma risk stratification
Authors: B., et al., Lesnikoski.
Meeting: Poster Session 18
PS18-03 Poster #:
To elucidate the molecular heterogeneity of triple-negative breast cancers using BluePrint
Authors: Kaklamani, V.G., et al., respectively
Meeting: Poster Session 18
PS18-05 Poster #:
New gene expression profiles and investigator-initiated protocols in early-stage breast cancer are investigated by the FLEX real-world data platform.
Authors: Lee, L., et al., respectively
Session: Ongoing Posters for Trials
OT-12-01 Poster #:
These data underscore the mission of Agendia to help guide all patients during their clinical journey with the diagnosis and personalized treatment of breast cancer.